Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2022 Apr 29;11(9):1499.
doi: 10.3390/cells11091499.

A Phase II Study on the Effect of Taurisolo® Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study

Stefano Sanduzzi Zamparelli  1 , Ludovica Capitelli  2 , Nicola Coppola  3 , Claudia Venditto  4 , Ciro Santoro  5 , Giuseppe Annunziata  6 , Dario Bruzzese  7 , Nunzia Cuomo  8 , Ivan Gentile  9   10 , Marialuisa Bocchino  4 , Alessandro Sanduzzi Zamparelli  4   10
Affiliations
Clinical Trial

A Phase II Study on the Effect of Taurisolo® Administered via AEROsol in Hospitalized Patients with Mild to Moderate COVID-19 Pneumonia: The TAEROVID-19 Study

Stefano Sanduzzi Zamparelli et al. Cells. .

Abstract

Background: Polyphenols are the largest class of bioactive compounds in plants, which are synthesized as secondary metabolites. In the last few years, interesting studies have demonstrated the efficacy of polyphenols against coronavirus infections.

Methods: we conducted a phase II multicentric clinical trial (TAEROVID-19) during the first wave of the COVID-19 pandemic in order to assess the safety and feasibility of Taurisolo® aerosol formulation in hospitalized patients suffering from SARS-CoV-2 pneumonia.

Results: we observed a rapid decline of symptoms and a low rate of intensive care in patients treated with Taurisolo®, with a faster decline of symptoms.

Conclusions: This is the first trial assessing the safety and feasibility of Taurisolo® aerosol formulation. We could argue that this treatment could act as an add-on therapy in the treatment of COVID-19 patients, owing to both its anti-inflammatory and antioxidant effects. Further controlled trials are needed, which may be of interest to evaluate the compound's efficacy.

Keywords: COVID-19 pneumonia; ICU access; polyphenols.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Most prevalent symptoms at COVID-19 pneumonia onset. Data are expressed as the percentage of patients.
Figure 2
Figure 2
Inflammatory parameters at the admission and at day seven after treatment.
Figure 3
Figure 3
Lung function parameters. P/F ratio increased significantly during the first seven days of treatment, rising from 292 ± 60.4 to 310 ± 73 (p = 0.033) as well as oxygen saturation (95.8 ± 2 at baseline vs. 97.1 ± 1.6 at day 7; p < 0.001). On the contrary, the observed increase in PAO2 did not reach statistical significance (72.8 ± 14 vs. 77.6 ± 11.4; p = 0.083).
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Cascella M., Rajnik M., Aleem A., Dulebohn S.C., Di Napoli R. Features, Evaluation, and Treatment of Coronavirus (COVID 19) StatPearls Publishing; Treasure Island, FL, USA: 2022. - PubMed
    1. Pan Y., Guan H., Zhou S., Wang Y., Li Q., Zhu T., Hu Q., Xia L. Initial CT Findings and Temporal Changes in Patients with the Novel Coronavirus Pneumonia (2019-nCoV): A Study of 63 Patients in Wuhan, China. Eur. Radiol. 2020;30:3306–3309. doi: 10.1007/s00330-020-06731-x. - DOI - PMC - PubMed
    1. Zou L., Ruan F., Huang M., Liang L., Huang H., Hong Z., Yu J., Kang M., Song Y., Xia J., et al. SARS-CoV-2 Viral Load in Upper Respiratory Specimens of Infected Patients. N. Engl. J. Med. 2020;382:1177–1179. doi: 10.1056/NEJMc2001737. - DOI - PMC - PubMed
    1. Grasselli G., Greco M., Zanella A., Albano G., Antonelli M., Bellani G., Bonanomi E., Cabrini L., Carlesso E., Castelli G., et al. Risk Factors Associated with Mortality Among Patients with COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern. Med. 2020;180:1345–1355. doi: 10.1001/jamainternmed.2020.3539. - DOI - PMC - PubMed
    1. Siddiqi H.K., Mehra M.R. COVID-19 Illness in Native and Immunosuppressed States: A Clinical-Therapeutic Staging Proposal. J. Heart Lung Transplant. 2020;39:405–407. doi: 10.1016/j.healun.2020.03.012. - DOI - PMC - PubMed

Publication types

LinkOut - more resources